Clermont Ferrand cedex 01, France Clinical Trials

A listing of Clermont Ferrand cedex 01, France clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors

The study will determine the recommended Phase 2 dose (RP2D) of ABBV-151 administered as monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-151 alone and in combination with budigalimab. The study will consist of 2 phases: dose escalation …

Centre Leon Berard /ID# 218515
 (84.0 away) Contact site
  • 17 views
  • 31 May, 2021
  • +37 other locations
Study of Tinostamustine First-in-Class Alkylating HDACi Fusion Molecule in Relapsed/Refractory Hematologic Malignancies

This study evaluates the efficacy, safety and pharmacokinetics of tinostamustine (EDO-S101) in patients with relapsed/refractory hematologic malignancies. All patients will receive tinostamustine.

sezary syndrome
angioimmunoblastic t-cell lymphoma
hodgkin's disease
t-cell lymphoma
lymphoma
CHU ESTAING Service de th rapie Cellulaire et h matologique Clinique
 (1.6 away) Contact site
  • 0 views
  • 14 Jun, 2021
  • +25 other locations
A Study to Determine the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of ABBV-927 With ABBV-368 Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors. This study consists of 2 main parts, a dose-escalation phase and a dose-expansion phase. The dose-expansion phase can begin once the recommended phase 2 dose/maximum …

breast adenocarcinoma
solid neoplasm
primary cancer
progesterone receptor
paclitaxel
Centre Leon Berard /ID# 217910
 (85.5 away) Contact site
  • 52 views
  • 26 Jan, 2021
  • +30 other locations
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who have received standard therapy

blast cells
hematologic malignancy
IDH2
Centre Hospitalier Lyon Sud
 (9.9 away) Contact site
  • 0 views
  • 18 Jun, 2021
  • +45 other locations
SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic Paraplegias

Cerebellar ataxias (CA) and spastic paraplegias (SP) are genetically and clinically very heterogeneous. More than 40 loci are already known but the number of phenotypes is even greater suggesting further genetic heterogeneity. These progressive disorders are often severe and fatal, due to the absence of specific therapy. The SPATAX network …

progressive ataxia
genetic analysis
genetic counselling
ataxia
paraplegia
H pitaux de Clermont-Ferrand
 (1.6 away) Contact site
  • 258 views
  • 07 Nov, 2020
  • +23 other locations